C5a/C5aR1 study in IgG4-related disease
Treatments studied
Part of Immune system & allergy clinical trials.
This study looks at a specific immune signal (C5a/C5aR1) in IgG4-related disease to see if blocking that signal could be a future treatment. It compares blood samples from people with active disease, people in remission, and healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with IgG4-related disease using the 2019 international criteria.
- Your disease must be active, meaning you have symptoms or inflammation in at least one organ.
- You are not taking more than 5 mg of prednisone daily, or stopped that dose less than a month ago.
- You have not taken immunosuppressant drugs (like methotrexate) in the last 3 months, or biologic drugs (like rituximab) in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This trial tests if inebilizumab is safe and works well for children with IgG4-related disease (a condition causing swelling in various organs). It may be an option if your child needs treatment beyond steroids.
This trial tests if lenalidomide, taken as a pill, can help prevent IgG4-related disease from coming back (relapsing) in people who are already in remission on low-dose steroids.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests a new drug called ACE1831 for people with active IgG4-related disease that affects more than one organ. It aims to see if the drug can safely control the disease and reduce the need for steroids.
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
Hear when a new Immunoglobulin G4-Related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.